GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Construction In Progress

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Construction In Progress : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Construction In Progress?


Infant Bacterial Therapeutics AB Construction In Progress Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Construction In Progress Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines